BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

Phase 2 Unknown 30 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.

Timeline

Start: 2019-01-01
Primary completion: 2022-01-01
Completion: 2023-01-01

Publications

Zhao H, Zhang MY, Shen KN, Feng J, Cao XX, Duan MH, Zhou DB, Zhang L, Li J. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD. Blood. 2023 May 25;141(21):2654-2657. doi: 10.1182/blood.2023020009. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Subcutaneous
Subject	Cyclophosphamide	Other / unclassified	300 mg/m2	Oral
Subject	Dexamethasone	Small molecule	20 mg	Oral

BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

Summary

Timeline

Publications

Drugs

Indications